Aligos Therapeutics, Inc. 8-K

What Happened
Aligos Therapeutics, Inc. (Nasdaq: ALGS) filed a Form 8-K on May 7, 2026 to report results of operations and financial condition. The company issued a press release dated May 7, 2026, which is attached to the 8-K as Exhibit 99.1 and incorporated by reference into the filing.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Press release attached as Exhibit 99.1 and incorporated by reference.
• The filing additionally includes an Inline XBRL interactive data file (cover page embedded).
• Ticker: ALGS (Aligos Therapeutics, Inc.).

Why It Matters
This 8-K is the company’s formal disclosure that it has publicly released an update on its financial results and condition. Retail investors should read the attached May 7, 2026 press release for the specific earnings or quarterly results, revenue figures, and any commentary management provided. The disclosure is material for tracking Aligos’s financial performance and could be relevant for short‑term trading or longer‑term investment decisions.